GlobeNewswire

SECUDE appoints Eric Kang as Vice President (Technology) in US

Share

In his second stint, Eric is responsible for Marketing, Sales and Operations in the United States

LUCERNE, Switzerland, May 03, 2019 (GLOBE NEWSWIRE) -- SECUDE, SAP partner and a leading data security provider specializing in data security for SAP Enterprise software, today announced that it has appointed Mr. Eric Kang as Vice President (Technology) and Evangelist for SECUDE IT Security, LLC in the United States. He will be responsible for sales, marketing and operations in the Americas and will work in close collaboration with our R&D and Product Management departments. Eric will be operating from Seattle, Washington.

In his first stint, Eric was with SECUDE from 2006 to 2008 as Senior Vice President of Operation for the North American region.

I am pleased to be with SECUDE again and this time head the organization’s sales and operations in the United States. SECUDE’s unique work culture assures operational freedom with close always-at-hand support whenever required. Such a model works great for this region, which has immense potential and is a key market for SECUDE’s world-class data security products,” says Eric Kang.

Welcoming Eric, Dr. Heiner Kromer, Chairman, SECUDE, states: “Eric is an experienced IT architect with in-depth expertise in SAP technology and IT application security. He is also very passionate about artificial intelligence and machine learning. He has proven expertise in complex business operations. We are pleased with his performance in 2006 and 2008 and are sure that he will take SECUDE up several notches in the US.

Eric has an extensive repertoire in IT Architecture, Project Management, Mentoring and Entrepreneurship knowhow. He holds MS degrees in Mathematics and Computer Engineering from the University of Minnesota and completed several PhD level researches.

He can be contacted at eric.kang@secude.com and on LinkedIn at https://www.linkedin.com/in/erickang/.

About SECUDE
SECUDE is an established global security solutions provider offering innovative IT data protection for SAP users.

Founded as a joint venture between SAP and Fraunhofer Institute in 1996, SECUDE maintained a close SAP technology partnership and became a reliable resource for security solutions for the SAP market with ‘Single Sign-On’ for SAP, which was acquired by SAP in 2011. With a focus on making business process for data protection efficient and automated with little or no user interference, SECUDE’s goal is to provide ease of use while minimizing cost of rollout and operations.

Leveraging its 20-plus years of experience in SAP security and business process know-how in protecting enterprise IP and data, SECUDE launched HALOCORE® as a holistic approach to protect SAP data exports.

SECUDE’s solutions are trusted by many Fortune 500 and DAX listed companies. With branches in Europe, North America and Asia, SECUDE supports customers with the implementation of IT security strategies through a global network. For more information, visit www.secude.com and follow our social media channels: LinkedIn, Twitter and YouTube . 

For more information, please contact:

Ramakrishnan Ramani
Manager – Marketing & Communication

communication@secude.com  |  +91-7418172539

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso20.8.2019 08:00:00 CESTPress release

Metso Corporation, Stock exchange release on August 20, 2019, at 9:00 a.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the holding of mutual funds managed by BlackRock, Inc. of the total amount of shares and financial instruments entitling to shares of Metso. On August 16, 2019, BlackRock Inc.'s direct holding in Metso shares and in financial instruments entitling to shares fell below the 5 percent threshold. On August 14, 2019, BlackRock, Inc.'s total position in Metso amounted to less than 5 percent of Metso’s shares and votes. Metso’s total number of shares and votes is 150,348,256. BlackRock, Inc.’s holdings according to the notification: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A + B) Res

Intention to list & Company Description20.8.2019 08:00:00 CESTPress release

GG St. Kongensgade 100 og 106 P/S Nasdaq First North, Copenhagen, Bond Market Ticker: GGSTK; ISIN: DK0030444401 For release: 20 August 2019 Intention to list the company’s floating rate (7%) secured bond loan 2019/2020 and company description The Director of GG St. Kongensgade 100 og 106 P/S announces that the Company intends to list its floating rate 7% secured bond loan 2019/2020 for trading on Nasdaq First North, Copenhagen. In connection with this, the Company has prepared a Company Description which has been approved by Nasdaq Copenhagen A/S. A copy of the Company Description accompanies this release and it may also be downloaded from the Investor Relations section of the Company’s website at www.gefiongroup.com The Company anticipates the first day of trading in its Bonds being 23 August 2019. GG St. Kongensgade 100 og 106 P/S, incorporated under the laws of Denmark with business registration number 38 30 68 47, having its registered office at c/o Gefion Group A/S, Østergade 1, 2